Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Hassan Website

Raffit Hassan, M.D.

Selected Publications
1)  Hassan R, Broaddus VC, Wilson S, Liewehr DJ, Zhang J.
Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts.
Clin. Cancer Res. 13: 7166-71, 2007. [Journal]
2)  Hassan R, Ebel W, Routhier EL, Patel R, Kline JB, Zhang J, Chao Q, Jacob S, Turchin H, Gibbs L, Phillips MD, Mudali S, Iacobuzio-Donahue C, Jaffee EM, Moreno M, Pastan I, Sass PM, Nicolaides NC, Grasso L.
Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.
Cancer Immun. 7: 20, 2007. [Journal]
3)  Hassan R, Ho M.
Mesothelin targeted cancer immunotherapy.
Eur. J. Cancer. 44: 46-53, 2008. [Journal]
4)  Walshe JM, Gal A, Murray DR, Premkumar A, Berman D, Hassan R.
Malignant mesothelioma of the inguinal canal with an unusually long survival.
Am. J. Clin. Oncol. 31: 306-7, 2008. [Journal]
5)  Zhang Y, Xiang L, Hassan R, Pastan I.
Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors.
Proc. Natl. Acad. Sci. U.S.A. 104: 17099-104, 2007. [Journal]
6)  Steinbach D, Onda M, Voigt A, Dawczynski K, Wittig S, Hassan R, Gruhn B, Pastan I.
Mesothelin, a possible target for immunotherapy, is expressed in primary AML cells.
Eur. J. Haematol. 79: 281-6, 2007. [Journal]
7)  Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, Pastan I.
Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers.
Clin. Cancer Res. 13: 5144-9, 2007. [Journal]
8)  Hassan R, Pass H.
Mesothelioma. Volume .
Physicians Information and Education Resource, American College of Physicians; http://pier.acpoline.org; 2007. In Press. [Book]
9)  Yan T, Hassan R, Welch L, Sugarbaker P.
Advances in diffuse malignant peritoneal mesothelioma.
Oncol. Rev. 1: 53-64, 2007. [Journal]
10)  Ho M, Bera TK, Willingham MC, Onda M, Hassan R, FitzGerald D, Pastan I.
Mesothelin expression in human lung cancer.
Clin. Cancer Res. 13: 1571-5, 2007. [Journal]
11)  Filpula D, Yang K, Basu A, Hassan R, Xiang L, Zhang Z, Wang M, Wang Q, Ho M, Beers R, Zhao H, Peng P, Zhou J, Li X, Petti G, Janjua A, Liu J, Wu D, Yu D, Zhang Z, Longley C, FitzGerald D, Kreitman RJ, Pastan I.
Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice.
Bioconjug. Chem. 18: 773-784, 2007. [Journal]
12)  Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ.
Immunotoxin treatment of cancer.
Annu. Rev. Med. 58: 221-37, 2007. [Journal]

This page was last updated on 8/11/2008.